Testing coramitug for ATTR amyloid heart disease
Part of Heart & circulation clinical trials.
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years of age or older.
- You must have a confirmed diagnosis of ATTR amyloidosis with heart involvement (called ATTR-CM).
- You must have had heart failure symptoms or a hospital stay for heart failure in the past 2 years.
- You cannot be pregnant, breastfeeding, or planning to become pregnant.
- You cannot be taking part in any other experimental drug study right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
This trial uses special heart imaging to better measure how amyloid deposits affect the heart in people with certain diagnoses. The goal is to understand which imaging signals match your disease and to see if this approach could help guide care.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study uses a new imaging technique (PET scan with a tracer called evuzamitide) to detect a type of heart disease called cardiac amyloidosis in patients whose standard heart scans were unclear but who have elevated levels of a new blood marker (TAD1). The goal is to find a better way to diagnose this condition.
Hear when a new Transthyretin Amyloid Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.